Welcome to our dedicated page for ADGI news (Ticker: ADGI), a resource for investors and traders seeking the latest updates and insights on ADGI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ADGI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ADGI's position in the market.
Adagio Therapeutics (NASDAQ: ADGI) has announced its 2022 Annual Meeting of Stockholders, scheduled for May 26, 2022, at 8:30 a.m. Eastern Time, to be held virtually. Further details will be provided in the upcoming Proxy Statement with the SEC. Adagio focuses on developing antibody-based treatments for infectious diseases, leveraging advanced engineering for improved efficacy and manufacturability. Their investigational monoclonal antibody, ADG20, is designed to offer broad protection against COVID-19, though it is not yet approved for use, and its safety and efficacy remain unestablished.
Adagio Therapeutics, Inc. (Nasdaq: ADGI) announced the appointment of David Hering as interim CEO, effective immediately, following the resignation of Tillman Gerngross. Hering, who is also the Chief Operating Officer, is tasked with leading the company while a formal CEO search is conducted. Adagio aims to expand its portfolio of SARS-CoV-2 monoclonal antibodies and evaluate data from ongoing clinical trials for ADG20, an investigational treatment. The company has secured production capacity for ADG20 and highlighted its achievements in funding and trial advancement.
Adagio Therapeutics (Nasdaq: ADGI) announced its strategic initiatives for the ADG20 program, an investigational monoclonal antibody for COVID-19 prevention and treatment. Key plans include analyzing clinical data from ongoing trials to evaluate the 300mg dose, testing higher doses, and enhancing ADG20's efficacy against the Omicron variant. Furthermore, the company aims to explore additional monoclonal antibodies to improve neutralization breadth. ADG20 has shown in vitro activity against various SARS-CoV-2 variants, although reduced effectiveness was noted against the BA.2 Omicron lineage.
Adagio Therapeutics (Nasdaq: ADGI) announced a CEO succession plan on February 18, 2022, with current CEO Tillman Gerngross agreeing to resign. The board plans to appoint David Hering, the current COO, as Interim CEO. Hering brings over 25 years of industry experience, previously leading Pfizer's mRNA Global Franchise and launching its COVID-19 vaccine. Adagio focuses on developing antibody-based solutions for infectious diseases and has secured manufacturing for its investigational monoclonal antibody, ADG20, although its safety and efficacy remain unproven.
Adagio Therapeutics (Nasdaq: ADGI) announces that recent studies confirm its lead monoclonal antibody, ADG20, exhibits neutralizing activity against the Omicron variant of SARS-CoV-2. This antibody shows comparable potency to other authorized mAbs, with an IC50 of 0.4 to 1.1 µg/mL. In light of these findings, Adagio is collaborating with the FDA to update its clinical trial protocols, including potential dose adjustments. The company is also exploring additional mAbs to enhance treatment options against Omicron and future variants. Preliminary research findings are expected by Q1 2022.
Adagio Therapeutics (Nasdaq: ADGI) announced that CEO Tillman Gerngross will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 7:30 a.m. ET. A live webcast will be available on the company’s investor website and will be archived for 60 days.
Adagio focuses on developing antibody-based treatments for infectious diseases, including COVID-19 and influenza. The company aims to provide effective and affordable solutions, emphasizing broad accessibility to their therapies.
Adagio Therapeutics (Nasdaq: ADGI) announced concerning in vitro data showing a greater than 300-fold reduction in the neutralizing activity of its investigational monoclonal antibody ADG20 against the Omicron variant of SARS-CoV-2. The company plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial in South Africa due to this finding. ADG20, previously effective against other variants, is undergoing further research to assess its efficacy against COVID-19 variants. Adagio aims to engage regulatory bodies regarding ADG20's potential in COVID-19 treatment.
Adagio Therapeutics (ADGI) announced ongoing in vitro studies to evaluate the effectiveness of its monoclonal antibody, ADG20, against the Omicron variant of SARS-CoV-2. Anticipating Emergency Use Authorization (EUA) submissions for ADG20 in mid-2022, the company has built up inventory with 4 million doses ready for distribution. ADG20 aims to provide broad neutralizing activity against SARS-CoV-2 variants, offering up to one year of protection with a single injection. Clinical trials and regulatory discussions are highlighted as key ongoing activities to support ADG20's deployment against COVID-19.
Adagio Therapeutics (Nasdaq: ADGI) appointed Jill Andersen as Chief Legal Officer, enhancing its leadership team. With over 20 years in the pharmaceutical sector, Andersen's experience includes critical roles at Oyster Point Pharma and Bristol Myers Squibb. Additionally, Redonda Miller and Ellen Marram join the board of directors, bringing invaluable insights from their respective backgrounds in clinical operations and consumer health. Adagio is focused on advancing its investigational antibody, ADG20, towards emergency use authorization for COVID-19 treatment.
Adagio Therapeutics (ADGI) announced FDA feedback supporting the planned Emergency Use Authorization (EUA) submission for ADG20, an investigational monoclonal antibody for COVID-19 prevention and treatment. The company is progressing in clinical trials, with interim efficacy data and a data package expected in Q2 2022. As of September 30, 2021, Adagio reported $666.3 million in cash, supporting operations into 2023, with R&D expenses of $49.4 million and a net loss of $60.4 million for Q3 2021.
FAQ
What is the market cap of ADGI (ADGI)?
